Tubulysins are another family of drugs that disrupt the cell's scaffolding. Antibody-linked versions are being studied to deliver their cell-killing action more selectively.
Tubulysin derivatives are tubulin-directed payloads distinct from auristatins and maytansinoids. A primary comparison of tubulysin antibody conjugates found that conjugation mode and site changed payload stability, pharmacokinetics and efficacy in a gastric cancer xenograft model. Results from a peptide or small-molecule tubulysin conjugate should not be described as antibody-conjugate evidence.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Tubulin inhibitor payloads, Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Tubulin inhibitor payloads, Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/